TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15456204

Group type: EXPERIMENTAL
Intervention: Home visit by a midwife from the maternity ward of the hospital
Number of subjects: 605
Study: 11442213

Group type: COMPARATOR
Intervention: Placebo and chloroquine treatment for symptomatic malaria infection
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo and monthly presumptive treatment with sulfamethoxazole-pyrimethamine (SP)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Monthly SP and thrice‐weekly vitamins A and C (VAC)
Number of subjects: 215
Study: 9474601

Group type: EXPERIMENTAL
Intervention: Silicone intraocular lenses (IOLs)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Polymethylmethacrylate (PMMA) intraocular lenses (IOLs)
Number of subjects: 119
Study: 7664433

Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg BID, n = 33)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (n = 16)
Number of subjects: 56
Study: 2666040

Group type: EXPERIMENTAL
Intervention: 400 mg acyclovir by mouth, twice daily, for 12 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Matching placebo by mouth, twice daily, for 12 weeks
Number of subjects: 24
Study: 1052834

Group type: EXPERIMENTAL
Intervention: Unilateral sinusoidal E.C.T.
Number of subjects: 66

Group type: COMPARATOR
Intervention: Bilateral sinusoidal E.C.T.
Number of subjects: 66

Group type: COMPARATOR
Intervention: Pulse E.C.T.
Number of subjects: 66
Study: 30916007

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine sedation with caudal block
Number of subjects: 104

Group type: COMPARATOR
Intervention: General anaesthesia with caudal block
Number of subjects: 104
Study: 28982380

Group type: EXPERIMENTAL
Intervention: 'Who's Challenging Who?' (WCW) training intervention
Number of subjects: 236

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 236
Study: 25734713

Group type: EXPERIMENTAL
Intervention: L‐PRF (Leukocyte‐ and platelet‐rich fibrin)
Number of subjects: 44

Group type: COMPARATOR
Intervention: CTG (free connective tissue grafts)
Number of subjects: 44
Study: 24142213

Group type: EXPERIMENTAL
Intervention: Calatonia technique
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo (non-intentional touches)
Number of subjects: 116
Study: 22448476

Group type: EXPERIMENTAL
Intervention: Panavir added to combined treatment
Number of subjects: 0
Study: 19834767

Group type: EXPERIMENTAL
Intervention: Class II hysterectomy (modified radical hysterectomy)
Number of subjects: 520

Group type: COMPARATOR
Intervention: Class I hysterectomy (extrafascial hysterectomy)
Number of subjects: 520
Study: 16317106

Group type: EXPERIMENTAL
Intervention: Bitter Orange (900 mg dietary supplement extract standardized to 6% synephrine)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 14744573

Group type: EXPERIMENTAL
Intervention: Flumazenil (1 mg i.v. loading dose followed by 0.5 mg i.v. infusion over 30 min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 8
Study: 11384023

Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:80,000 epinephrine (adrenaline)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 3% prilocaine with 0.03IU/ml felypressin
Number of subjects: 10
Study: 8996293

Group type: EXPERIMENTAL
Intervention: Dalteparin (Fragmin)
Number of subjects: 971

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 971
Study: 8499580

Group type: EXPERIMENTAL
Intervention: 25 mg fluvoxamine maleate
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 50 mg fluvoxamine maleate
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 100 mg fluvoxamine maleate
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (all doses)
Number of subjects: 12
Study: 6356306

Group type: EXPERIMENTAL
Intervention: Fluocortin butylester (FCB) administered by inhalation through a special inhalator (Rhinolator) for three weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 31751388

Group type: EXPERIMENTAL
Intervention: Poultry workers with multidrug resistant (MDR) E. coli
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Poultry workers with absence of lavatory
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Poultry workers with history of diarrhea in last three months
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Poultry workers with farm/market existence for >10 years
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Poultry workers controlling for age with absence of lavatory
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Poultry workers controlling for age with history of diarrhea
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Poultry workers controlling for age with work exposure >10 years
Number of subjects: 122
Study: 30001982

Group type: EXPERIMENTAL
Intervention: Dienogest (DNG) + 3,3'-diindolylmethane (DIM)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Dienogest (DNG)
Number of subjects: 8
Study: 26845525

Group type: EXPERIMENTAL
Intervention: Parental problem-solving skills training (PSST)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 61
Study: 24682421

Group type: EXPERIMENTAL
Intervention: Clofarabine 5×10 mg/m²/day
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Clofarabine 15 mg/m²/day
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Clofarabine 10 mg/m²/day
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Clofarabine combined with cytosine arabinoside and idarubicin
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Clofarabine (various doses)
Number of subjects: 25
Study: 22437295

Group type: EXPERIMENTAL
Intervention: FJ injections (FJI)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: FJ radiofrequency denervation (FJRF)
Number of subjects: 100
Study: 19491895

Group type: EXPERIMENTAL
Intervention: XELOX (capecitabine plus oxaliplatin) as first-line chemotherapy
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: XELOX (capecitabine plus oxaliplatin) as second-line chemotherapy
Number of subjects: 2

Group type: COMPARATOR
Intervention: XELOX (capecitabine plus oxaliplatin)
Number of subjects: 2

Group type: COMPARATOR
Intervention: FOLFOX4 (5-fluorouracil/folinic acid and oxaliplatin)
Number of subjects: 2
Study: 17453864

Group type: EXPERIMENTAL
Intervention: Testosterone patch (300 mug/24 h)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 99
Study: 16467024

Group type: EXPERIMENTAL
Intervention: 100% TCA
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 70% TCA
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 50% TCA
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: All strengths of TCA
Number of subjects: 51
Study: 14998224

Group type: EXPERIMENTAL
Intervention: Pharmacotherapeutic management of arrhythmias
Number of subjects: 0
Study: 10779453

Group type: EXPERIMENTAL
Intervention: beta-radiation therapy with 90-yttrium, 20.6 Gy dose at 1.0 mm from the balloon surface
Number of subjects: 50

Group type: COMPARATOR
Intervention: placebo group of gamma-WRIST
Number of subjects: 50
Study: 8904618

Group type: EXPERIMENTAL
Intervention: Fluconazole 50 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Fluconazole 100 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Fluconazole 200 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 1812307

Group type: EXPERIMENTAL
Intervention: Ice bag
Number of subjects: 40

Group type: COMPARATOR
Intervention: Heat lamp
Number of subjects: 40
Study: 6195239

Group type: EXPERIMENTAL
Intervention: Re-used haemodialysers cleaned with sodium hypochlorite and benzoic acid
Number of subjects: 206

Group type: COMPARATOR
Intervention: New haemodialysers
Number of subjects: 206
Study: 30010509

Group type: EXPERIMENTAL
Intervention: Higher intensity and dose exercise programs (5 days/week for four weeks)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Usual inpatient physical therapy care
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Higher intensity and dose exercise programs
Number of subjects: 75
Study: 28005247

Group type: EXPERIMENTAL
Intervention: Low-dose capecitabine plus docetaxel (capecitabine 825 mg/m2 twice daily, days 1-14; docetaxel 60 mg/m2, day 1 every 3 weeks)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Single-agent docetaxel (70 mg/m2, day 1 every 3 weeks)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Low-dose capecitabine plus docetaxel
Number of subjects: 162

Group type: COMPARATOR
Intervention: Single-agent docetaxel
Number of subjects: 162
Study: 26227087

Group type: EXPERIMENTAL
Intervention: FDC fenofibrate/simvastatin 145/20 mg or 145/40 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: FDC fenofibrate/simvastatin
Number of subjects: 0
Study: 22345693

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 600
Study: 21903052

Group type: EXPERIMENTAL
Intervention: Functional SYNTAX score (FSS)
Number of subjects: 497

Group type: COMPARATOR
Intervention: Classic SYNTAX score (SS)
Number of subjects: 497
Study: 19657998

Group type: EXPERIMENTAL
Intervention: XRCC1 194Trp allele
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Patient group (B-cell lymphoma cases)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: XRCC1 194Arg/Trp genotype
Number of subjects: 85
Study: 16387792

Group type: EXPERIMENTAL
Intervention: Variant angina patients
Number of subjects: 12

Group type: COMPARATOR
Intervention: Coronary artery disease (CAD) patients
Number of subjects: 12
Study: 15662751

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 11065066

Group type: EXPERIMENTAL
Intervention: Duration of exclusive breastfeeding (categorized as never, <4 months, or ≥4 months) among children with maternal asthma
Number of subjects: 1043

Group type: COMPARATOR
Intervention: Duration of exclusive breastfeeding (categorized as never, <4 months, or ≥4 months) among children without maternal asthma
Number of subjects: 1043
Study: 9610957

Group type: EXPERIMENTAL
Intervention: Plasma thrombomodulin
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: von Willebrand factor antigen
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: tissue factor
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: plasminogen activator inhibitor antigen
Number of subjects: 31
Study: 8471513

Group type: EXPERIMENTAL
Intervention: Psoralen-UVB treatment
Number of subjects: 15

Group type: COMPARATOR
Intervention: UVB alone
Number of subjects: 15
Study: 29667153

Group type: EXPERIMENTAL
Intervention: Rehab + EAAs (8 g/day)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Rehab only
Number of subjects: 83

Group type: COMPARATOR
Intervention: Rehab + placebo
Number of subjects: 83
Study: 29879707

Group type: EXPERIMENTAL
Intervention: Intradialytic aerobic training 3 times a week for 4 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 26747406

Group type: EXPERIMENTAL
Intervention: Affected trigeminal nerve (TGN)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Unaffected trigeminal nerve (TGN)
Number of subjects: 40
Study: 23748568

Group type: COMPARATOR
Intervention: Splinting (n=20)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Surgical treatment (open reduction and stabilization with screws and wires, n=29)
Number of subjects: 56
Study: 23083656

Group type: EXPERIMENTAL
Intervention: Saw palmetto (Serenoa repens)
Number of subjects: 339

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Combined cohort analysis
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Overall lower urinary tract symptoms (excluding nocturia)
Number of subjects: 339
Study: 20448003

Group type: EXPERIMENTAL
Intervention: Presenter conflict
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Researcher conflict
Number of subjects: 515

Group type: COMPARATOR
Intervention: No conflict
Number of subjects: 515
Study: 18029105

Group type: EXPERIMENTAL
Intervention: Halstead-type radical mastectomy
Number of subjects: 1665

Group type: EXPERIMENTAL
Intervention: Total mastectomy and radiotherapy
Number of subjects: 1665

Group type: EXPERIMENTAL
Intervention: Total mastectomy alone
Number of subjects: 1665
Study: 15824927

Group type: EXPERIMENTAL
Intervention: 99mTc-sestamibi/18FDG DISA SPECT
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 99mTc-sestamibi/18FDG DISA SPECT (visual analysis)
Number of subjects: 58
Study: 11463367

Group type: EXPERIMENTAL
Intervention: Protocol-directed weaning
Number of subjects: 223

Group type: COMPARATOR
Intervention: Physician-directed weaning
Number of subjects: 223
Study: 9713665

Group type: EXPERIMENTAL
Intervention: HIV-risk Screening Instrument (HSI) developed in Phase 1
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: HIV-risk Screening Instrument (HSI) used in Phase 2
Number of subjects: 459
Study: 7527105

Group type: EXPERIMENTAL
Intervention: Trandolapril 1 mg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Trandolapril 2 mg
Number of subjects: 27
Study: 2725451

Group type: EXPERIMENTAL
Intervention: Sprinters
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Students in PAE
Number of subjects: 32

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Witnesses
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Divided attention condition
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sprinters vs Controls
Number of subjects: 32
Study: 4599858

Group type: EXPERIMENTAL
Intervention: Ampicillin plus probenecid (3.5 g ampicillin with 1.0 g probenecid)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Amoxicillin alone (3.0 g)
Number of subjects: 114
Study: 30934043

Group type: EXPERIMENTAL
Intervention: Immediate loading protocol
Number of subjects: 22

Group type: COMPARATOR
Intervention: Delayed loading protocol
Number of subjects: 22
Study: 28337821

Group type: EXPERIMENTAL
Intervention: Care as usual + Mindfulness-based stress reduction (CAU + MBSR)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 107
Study: 24667900

Group type: EXPERIMENTAL
Intervention: Home-based hand exercises with HOA information
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Home-based hand exercises
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (information only)
Number of subjects: 80
Study: 23683738

Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Nitroprusside
Number of subjects: 240

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 240
Study: 21485024

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) plus methotrexate (MTX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus methotrexate (MTX)
Number of subjects: 0
Study: 18045731

Group type: EXPERIMENTAL
Intervention: Carboxyaminoimidazole (CAI) 250mg daily
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study: 16818663

Group type: EXPERIMENTAL
Intervention: Selenomethionine
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 14521653

Group type: EXPERIMENTAL
Intervention: Long QT syndrome patients (LQTS)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Short episodes of polymorphic atrial tachyarrhythmias (polyAT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: LQTS patients with polyAT
Number of subjects: 10
Study: 10984335

Group type: EXPERIMENTAL
Intervention: Sleep deprivation (17-19 hours without sleep)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Sleep deprivation (longer periods without sleep)
Number of subjects: 39
Study: 8773867

Group type: EXPERIMENTAL
Intervention: Epidural hydromorphone (0.6 mg)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Epidural morphine (3 mg)
Number of subjects: 46
Study: 1299733

Group type: EXPERIMENTAL
Intervention: Peri-operative antibiotics for clean-contaminated (class B) and contaminated (class C) cases only.
Number of subjects: 400

Group type: COMPARATOR
Intervention: Routine group received prolonged antibiotics.
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: No antibiotics for clean cases (class A).
Number of subjects: 400
Study: 6380856

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg orally 4 times a day during hospitalization + Metoprolol 15 mg intravenously 20 min after initial administration, then 50 mg 4 times a day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo + Metoprolol 15 mg intravenously 20 min after initial administration, then 50 mg 4 times a day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nifedipine + Metoprolol
Number of subjects: 30
Study: 28921723

Group type: EXPERIMENTAL
Intervention: Prophylactic cefalexin (22 mg/kg twice daily)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (no prophylactic cefalexin)
Number of subjects: 17
Study: 27139441

Group type: EXPERIMENTAL
Intervention: Mebendazole
Number of subjects: 1760

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1760
Study: 24716713

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) at 4 Joules
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) at 6 Joules
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) at 8 Joules
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (0 Joules)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) protocol that achieved the best muscle performance in phase 1
Number of subjects: 0
Study: 22976529

Group type: EXPERIMENTAL
Intervention: Spanish PFDI-20
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Spanish PFIQ-7
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Spanish QUID
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Spanish 3IQ
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Spanish-English agreement for individual items
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: PFDI-20, PFIQ-7, QUID subscales scores
Number of subjects: 78
Study: 20874462

Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 159

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 159
Study: 18400585

Group type: EXPERIMENTAL
Intervention: Cetrorelix 0.25 mg
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Cetrorelix 0.2 mg
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Cetrorelix 0.15 mg
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (LA) 0.5 mg/day
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Single half-dose LA depot 1.88 mg
Number of subjects: 251
Study: 16099784

Group type: EXPERIMENTAL
Intervention: Self-help guidebook
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Self-help group meeting (in addition to guidebook)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Control group (receiving neither intervention)
Number of subjects: 420
Study: 12795797

Group type: EXPERIMENTAL
Intervention: 0.5% chlorhexidine gel
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 43
Study: 10599334

Group type: EXPERIMENTAL
Intervention: Thalidomide 100 mg per day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thalidomide 300 mg per day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8555849

Group type: EXPERIMENTAL
Intervention: Percutaneous endoscopic gastrostomy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nasogastric tube feeding
Number of subjects: 30
Study: 2042567

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: ST-segment deviation in ≥2 leads during chest pain (in subset of 62 patients)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Total number of leads with ST changes
Number of subjects: 90
Study: 6857583

Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg four times per day for three days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salbutamol treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indomethacin reintroduced while salbutamol continued
Number of subjects: 0
Study: 3878718

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methohexitone
Number of subjects: 0
Study: 29147795

Group type: EXPERIMENTAL
Intervention: Pregabalin 2 mg/kg twice daily
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 27401508

Group type: EXPERIMENTAL
Intervention: Prophylactic fentanyl pectin nasal spray (FPNS) 15%-25% of total daily opioid dose
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 24636877

Group type: EXPERIMENTAL
Intervention: Oral etoposide
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Vincristine and bleomycin
Number of subjects: 92

Group type: COMPARATOR
Intervention: Vincristine alone
Number of subjects: 92
Study: 22933567

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 10122

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 10122
Study: 20540767

Group type: EXPERIMENTAL
Intervention: Esomeprazole 5 or 10 mg daily (< 20 kg) or 10 or 20 mg daily (≥ 20 kg) for 8 weeks
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 109
Study: 18946010

Group type: EXPERIMENTAL
Intervention: Fluoride application leading to CaF(2) formation on enamel
Number of subjects: 10
Study: 15992569

Group type: EXPERIMENTAL
Intervention: Postoperative assessment using General Health Questionnaire (GHQ‐28)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Illness Perception Questionnaire (IPQ)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Mental Adjustment to Cancer Scale (MAC)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Eysenck Personality Scales (EPS)
Number of subjects: 371
Study: 12790216

Group type: COMPARATOR
Intervention: Morphine 0.4 mg mL(‐1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Morphine 0.4 mg mL(‐1) + MgSO4 30 mg mL(‐1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Morphine 0.4 mg mL(‐1) + ketamine 1 mg mL(‐1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All groups (M, MM, MK)
Number of subjects: 90
Study: 10375052

Group type: EXPERIMENTAL
Intervention: 300 kcal/d very low calorie diet (VLCD) for 5 days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 900 kcal/d low calorie diet (LCD) for 6 months
Number of subjects: 20